Floatz logo

MEDI 6469

Colorectal Neoplasm

Providence Health & Servicesmonoclonal_antibodyPhase 1Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

118 Active assets in the Colorectal Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BBB
Eloxatin
Peking University Cancer Hospital & Institute
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Nottingham University Hospitals NHS Trust
Phase 4BBB
Irinotecan
Shanghai Zhongshan Hospital
Phase 4BBB
Regorafenib
Sergey Orlov, MD
Phase 4BB

View all 50 →

Same molecule, other indications

MEDI 6469 is also rated in:

aggressive B-cell non-Hodgkin lymphomaDormant
C
Indicative ·
33 / 100
View asset →
metastatic neoplasmDormant
C
Indicative ·
32 / 100
View asset →
breast cancerDormant
D
Indicative ·
31 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →